Flosequinan

Flosequinan

Clinical data
ATC code	C01DB01 (WHO)
Identifiers
IUPAC name (RS)-7-fluoro-3-methanesulfinyl-1-methyl-1,4-dihydroquinolin-4-one
CAS Number	76568-02-0 Y
PubChem CID	4474062
ChemSpider	3672315 N
UNII	6NB119DLU7
KEGG	D04195 Y
CompTox Dashboard (EPA)	DTXSID1048833
Chemical and physical data
Formula	C11H10FNO2S
Molar mass	239.26 g·mol−1
3D model (JSmol)	Interactive image
SMILES CN1C=C(C(=O)C2=C1C=C(C=C2)F)S(=O)C
InChI InChI=1S/C11H10FNO2S/c1-13-6-10(16(2)15)11(14)8-4-3-7(12)5-9(8)13/h3-6H,1-2H3 N Key:UYGONJYYUKVHDD-UHFFFAOYSA-N N
NY (what is this?)  (verify)

Flosequinan is a quinolone vasodilator that was discovered and developed by Boots UK and was sold for about a year under the trade name Manoplax. It had been approved in 1992 in the US and UK to treat people with heart failure who could not tolerate ACE inhibitors or digitalis.

Boots initiated a clinical trial called PROFILE to see if the drug could be useful in a wider population. The study was terminated early in 1993 due to increased mortality in the drug arm of the trial; preliminary results were published in a conference abstract by the PI Milton Packer and others, which promised data and analysis would be forthcoming in a future paper, which was finally published in 2017.

Boots withdrew it from the market in July 1993.